IMPROVEMENT OF OVERALL SURVIVAL WITH PRIMARY BREAST CANCER WITH MICROMESTASES TO THE BONE MARROW BY ADJUVANT CLODRONATE THERAPY
https://doi.org/10.17650/1994-4098-2009-0-1-2-53-58
Abstract
Supplementation of oral clodronate to postoperative adjuvant treatment for breast cancer (BC) considerably improves overall and relapse-free survival rates. The paper gives the results of a long-term follow-up of patients during a prospective randomized controlled study.
Subjects and methods. The study included patients with primary BC receiving clodronate in a dose of 1600 mg/day in combination with the conventional adjuvant therapy for BC.
Results. An analysis of 290 of 302 patients indicated a significant increase in overall survival in the clodronate group at a median fol- low-up of 103±12 months; during 8.5 years after primary surgical treatment, 20.4% and 40.7% of patients died in the clodronate and control groups, respectively (p = 0.04). The clodronate group did not show a considerable reduction in the rate of metastatic lesions in the bone and visceral organs or an increase in the relapse-free period following 36- and 55-month follow-ups.
Conclusions. The findings of better late overall survival rates confirm the results of earlier studies of oral clodronate in combination with the conventional adjuvant therapy for BC.
About the Authors
I.J. Diel
Department of Obstetrics and Gynecology, University of Heidelberg
Institute of Oncogynecology, Mannheim
Germany
Germany
A. Jaschke
Department of Obstetrics and Gynecology, University of Heidelberg
Germany
Germany
E. F. Solomayer
Department of Obstetrics and Gynecology, University of Tuebingen
Germany
Germany
S. Golan
Department of Obstetrics and Gynecology, University of Heidelberg
Germany
Germany
G. Bastert
Department of Obstetrics and Gynecology, University of Heidelberg
Germany
Germany
S. Sohn
Department of Obstetrics and Gynecology, University of Heidelberg
Germany
Germany
F. Schuetz
Department of Obstetrics and Gynecology, University of Heidelberg
Germany
Germany
References
1. American Cancer Society. Breast can- cer facts and figures, 2003—2004. Atlanta, GA: American Cancer Society Inc., 2003.
2. Ferlay J., Bray P., Pisani P., Parkin D.M. GLOBOCAN 2002: Cancer Incidence, mortality and prevalence worldwide. IARC CancerBase No. 5. Version 2.0. IARC Press 2004.
3. Coleman R.E., Rubens R.D. The clinical course of bone metastases from breast cancer. Br J Cancer 1987;55:61—6.
4. McCloskey E.V., Guest J.F., Kanis J.A. The clinical and cost consid- erations of bisphosphonates in preventing bone complications in patients with metastatic breast cancer or multiple myeloma. Drugs 2001;61:1253—74.
5. Paterson A.H. The role of adjuvant therapy with bisphosphonates in cancer. Am J Cancer 2004;3:25—39.
6. Mundy G. Preclinical models of bone metastases. Semin Oncol 2001;28:2—8.
7. Yoneda T., Michigami T., Yi B. et al. Actions of bisphosphonate on bone metastasis in animal models of breast car- cinoma. Cancer 2000;88:2979—88.
8. Powles T.J., Paterson A.H.G., Kanis J.A. et al. Randomized, placebo- controlled trial of clodronate in patients with primary operable breast cancer. J Clin Oncol 2002;20:3219—24.
9. Diel I.J., Solomayer E.F., Costa S.D. et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 1998;339:357— 63.
10. Diel I.J. Bisphosphonates in the prevention of bone metastases: current evi- dence. Semin Oncol 2001;28:75—80.
11. Powles T.J., Paterson A.H.G., McCloskey E. et al. Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]. Breast Cancer Res 2006; 8: R13.
12. Diel I.J., Kaufmann M., Goerner R. et al. Detection of tumor cells in bone marrow of patients with primary breast cancer: a prognostic factor for distant metastasis. J Clin Oncol 1992;10:1534—9.
13. Diel I.J., Kaufmann M., Costa S.D. et al. Micrometastatic breast cancer cells in bone marrow at primary surgery: prog- nostic value in comparison with nodal status. J Natl Cancer Inst 1996;88: 1652—8.
14. Janni W., Rack B., Sommer H. et al. Intra-mammary tumor location does not influence prognosis but influences the prevalence of axillary lymph-node metas- tases. J Cancer Res Clin Oncol 2003;129:503—10.
15. American Cancer Society. Breast cancer facts and figures, 2005—2006. Atlanta, GA: American Cancer Society Inc., 2005.
16. Saarto T., Blomqvist C., Virkkunen P., Elomaa I. Adjuvant clo- dronate treatment does not reduce the frequency of skeletal metastases in node- positive breast cancer patients: 5-year results of a randomized controlled trial. J Clin Oncol 2001;19:10—7.
17. Saarto T., Vehmanen L., Virkkunen P., Blomqvist C. Ten-year fol- low-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients. Acta Oncol 2004;43:650—6.
18. Mundy G.R. Realising the potential of anti-host cell therapy. Cancer Today 2004;(Suppl 1):6—8.
19. Mundy G.R. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002;2:584—93.
20. Boissier S., Ferreras M., Peyruchaud O. et al. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res 2000;60:2949—54.
21. Fromigue O., Lagneaux L., Body J.J. Bisphosphonates induce breast cancer cell death in vitro. J Bone Miner Res 2000;15:2211—21.
22. Fromigue O., Kheddoumi N., Body J.J. Bisphosphonates antagonise bone growth factors’ effects on human breast cancer cells survival. Br J Cancer 2003;89:178—84.
23. Rack B.K., Janni W., Schindlbeck C. et al. Effect of zoledronate on persisting isolated tumor cells (ITC) in the bone marrow (BM) of patients without recur- rence of early breast cancer. Proc Am Soc Clin Oncol 2004;23:abstr 9515.
24. Kanis J.A., Powles T.J., Paterson A.H.G. et al. Clodronate decreases the frequency of skeletal metas- tases in women with breast cancer. Bone 1996;19:663—7.
Review
For citations:
Diel I., Jaschke A., Solomayer E.F., Golan S., Bastert G., Sohn S., Schuetz F. IMPROVEMENT OF OVERALL SURVIVAL WITH PRIMARY BREAST CANCER WITH MICROMESTASES TO THE BONE MARROW BY ADJUVANT CLODRONATE THERAPY. Tumors of female reproductive system. 2009;(1-2):53-58. (In Russ.) https://doi.org/10.17650/1994-4098-2009-0-1-2-53-58
Views:
497
Email this article 